JZP150 (formerly PF-04457845) is an inhibitor of the enzyme
fatty acid amide hydrolase (FAAH), with an IC
50 of 7.2nM, and both
analgesic
An analgesic drug, also called simply an analgesic (American English), analgaesic (British English), pain reliever, or painkiller, is any member of the group of drugs used to achieve relief from pain (that is, analgesia or pain management). It ...
and
antiinflammatory effects in animal studies comparable to
naproxen.
JZP150 is currently being developed by Jazz Pharmaceuticals and is in a Phase 2 trial in the US for PTSD.
See also
*
FAAH inhibitor
Fatty acid amide hydrolase or FAAH (, oleamide hydrolase, anandamide amidohydrolase) is a member of the serine hydrolase family of enzymes. It was first shown to break down anandamide in 1993. In humans, it is encoded by the gene ''FAAH''.;
Fun ...
**
4-Nonylphenylboronic acid
4-Nonylphenylboronic acid is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 9.1nM, and 870x selectivity for FAAH over the related enzyme MAGL, which it inhibits with an IC50 of 7900nM. It is al ...
**
LY-2183240
**
URB-597
**
BIA 10-2474, problems in phase 1
References
{{Cannabinoids
Enzyme inhibitors
Trifluoromethyl compounds
Pyridazines
Pyridines